AstraZeneca and Moderna Therapeutics announce exclusive agreement to develop pioneering messenger RNA Therapeutics™ in cardiometabolic diseases and cancer

AstraZeneca and Moderna Therapeutics announce exclusive agreement to develop pioneering messenger RNA Therapeutics™ in cardiometabolic diseases and cancer

March 21, 2013

 

AstraZeneca today announced an exclusive agreement with Moderna Therapeutics to discover, develop and commercialise pioneering messenger RNA therapeutics™ for the treatment of serious cardiovascular, metabolic and renal diseases as well as cancer. Messenger RNA therapeutics™ are an entirely new treatment approach that enables the body to produce therapeutic protein in vivo, opening up new treatment options for a wide range of diseases that cannot be addressed today using existing technologies.

Flagship Ventures and Merck Research Labs Form Strategic Collaboration to Foster Early-Stage Life Sciences Innovation

Flagship Ventures and Merck Research Labs Form Strategic Collaboration to Foster Early-Stage Life Sciences Innovation

April 10, 2012

Initiative combines Merck’s drug development expertise with Flagship’s experience in building early stage companies

Joule appoints William J. Brady Jr. to Board of Directors

Joule appoints William J. Brady Jr. to Board of Directors

May 24, 2016

BEDFORD, Mass.--(BUSINESS WIRE)--Joule, a leading low carbon fuels company, today announced the appointment of William J. Brady Jr. to the company’s board of directors. Mr. Brady is an industry leader who brings extensive experience from his 25-year career at top-tier renewable fuels and chemicals companies.

Codiak BioSciences Names Jan Lötvall, M.D., Ph.D., Chief Scientist

Codiak BioSciences Names Jan Lötvall, M.D., Ph.D., Chief Scientist

May 17, 2016

WOBURN, Mass., May 17, 2016 /PRNewswire/ -- Codiak BioSciences Inc., a leading company in the field of exosome biology, today announced the appointment of Jan Lötvall, M.D., Ph.D., as Chief Scientist. As a member of the executive leadership team, Dr. Lötvall will report to Douglas E. Williams, Ph.D., President and CEO, and will continue his pioneering research on the potential of exosomes for therapeutic uses. He will begin his new position this summer, working on a consulting basis during his relocation from Gothenburg, Sweden.

Seres Therapeutics Announces Collaboration with University of Pennsylvania Researchers to Support the Development of Microbiome Therapeutics for Rare Genetic Metabolic Diseases and Inflammatory Bowel Disease

Seres Therapeutics Announces Collaboration with University of Pennsylvania Researchers to Support the Development of Microbiome Therapeutics for Rare Genetic Metabolic Diseases and Inflammatory Bowel Disease

May 12, 2016

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Seres Therapeutics, Inc. (NASDAQ:MCRB), a leading microbiome therapeutics platform company, today announced that it has entered into a multi-year collaboration with leading microbiome clinical-scientists from the University of Pennsylvania (Penn) to support the development of novel treatment approaches for certain rare genetic metabolic diseases including urea cycle disorders, and inflammatory bowel disease (IBD).

Seres Therapeutics Announces Appointment of Thomas J. DesRosier as Chief Legal Officer and Executive Vice President

Seres Therapeutics Announces Appointment of Thomas J. DesRosier as Chief Legal Officer and Executive Vice President

May 16, 2016

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Seres Therapeutics Inc. (NASDAQ:MCRB), a leading microbiome therapeutics company, announced today that it has appointed Thomas J. DesRosier as Chief Legal Officer and Executive Vice President. DesRosier will be responsible for global legal operations, as well as corporate compliance and quality assurance. He will also act as Secretary for Seres’ Leadership Team and its Board of Directors.

Seres Therapeutics Reports First Quarter Financial Results and Provides Operational Progress Update

Seres Therapeutics Reports First Quarter Financial Results and Provides Operational Progress Update

May 16, 2016

SER-109 Phase 2 study enrollment complete; results expected in mid-2016

Academic collaborations further microbiome therapeutic leadership in immuno-oncology, rare genetic diseases and other indications

$120 million upfront payment obtained from Nestlé Health Science

 

Seres Therapeutics Announces Broad Agreement with Memorial Sloan Kettering Cancer Center to Develop Microbiome Therapeutics for Hematopoietic Stem Cell Transplantation and Immuno-Oncology Treatment

Seres Therapeutics Announces Broad Agreement with Memorial Sloan Kettering Cancer Center to Develop Microbiome Therapeutics for Hematopoietic Stem Cell Transplantation and Immuno-Oncology Treatment

May 12, 2016

- Agreements provide IP license bolstering Company's strong patent portfolio -

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Seres Therapeutics, Inc. (NASDAQ:MCRB), a leading microbiome therapeutics platform company, today announced that it has entered into a strategic, multi-year research collaboration with Memorial Sloan Kettering Cancer Center (MSK). The collaboration will support the translation of novel discoveries from MSK laboratories into first-in-field microbiome therapeutics across multiple new cancer indications, where the microbiome may play a critical role.

Editas Medicine Announces First Quarter 2016 Results and Update

Editas Medicine Announces First Quarter 2016 Results and Update

May 16, 2016

Advancing pipeline and platform demonstrated by data presented at medical and scientific conferences as well as achievement of Juno Therapeutics milestone

Strengthened effort to develop medicines for cystic fibrosis through agreement with Cystic Fibrosis Foundation Therapeutics .

Robust foundation of intellectual, financial, and human capital positions Editas for long-term success

Editas Medicine Announces Agreement with Cystic Fibrosis Foundation Therapeutics to Advance New CRISPR/Cas9 Medicines

Editas Medicine Announces Agreement with Cystic Fibrosis Foundation Therapeutics to Advance New CRISPR/Cas9 Medicines

May 16, 2016

Editas to Receive up to $5 Million Award to Fund Genome Editing Research